This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical ...

Enliven Therapeutics has raced ahead with a 220.6% year to date return, yet the broader valuation checks and market multiples ...

Enliven Therapeutics (ELVN) added nearly 20% in the premarket on Thursday after the cancer drug developer posted updated results from a Phase 1 trial for its lead candidate ELVN-001 in patients with ...

Enliven Therapeutics Inc. (Nasdaq: ELVN), a Boulder-based, pre-revenue oncology drug developer, grew its expenses and net losses in the fourth quarter of 2023 and for the full 2023 fiscal year as two ...

The company says that across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population. ELVN-001 was well tolerated, with no ≥ Grade 3 treatment-related ...

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and ...

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in the ...

Drugs from a class called tyrosine kinase inhibitors have become standard treatments for some cancers, but the improved survival of patients taking these medicines introduces a new problem. As ...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 26, H.C. Wainwright increased its price target on Enliven Therapeutics, Inc.

Enliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share. The sale ...

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of ...

Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into early 2026 BOULDER, Colo., Nov. 09, 2023 ...